US Pharma and Biotech Summit
May 16
2024 is a pivotal year for US healthcare, in particular for the pharma and biotech industries. A presidential election will influence crucial policies on drug pricing and health financing for years to come. AI technologies are evolving from buzzwords to making an impact in drug R&D. Pharma is facing a huge patent cliff. And the biotech market appears to be pulling out of a slump just as the US economy executes the soft landing policymakers have hoped for.
The Financial Times US Pharma and Biotech Summit returns to New York in May 2024, partnered with Endpoints News for the first time. The event will gather biopharma leaders, regulators, investors and scientists to share unique insights about the year ahead and discuss the most important trends affecting the industry, and the country.
Join us to learn how the new market cycle will finance the next period of investing in innovation. Debate the dueling approaches to the US life expectancy crisis. Hear how artificial intelligence is splitting into two technological camps. And learn how drug makers, tech startups and insurers are fighting it out to redefine their relationship with patients.
